Novo Nordisk CEO: We are a cardiometabolic powerhouse

ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email

At the American Diabetes Association’s 2026 Scientific Sessions, CNBC’s Angelica Peebles sat down with Novo Nordisk CEO Mike Doustdar to discuss what to expect from Novo’s pipeline and strategy in the years to come. “We’re going to be very diversified,” he says. “But all of it within the area of cardiometabolics, per se. Diabetes, obesity, cardiometabolic, and some of the adjacencies.”